Browse DPYS

Summary
SymbolDPYS
Namedihydropyrimidinase
Aliases DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF01979 Amidohydrolase family
Function

Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyze the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.

> Gene Ontology
 
Biological Process GO:0006206 pyrimidine nucleobase metabolic process
GO:0006208 pyrimidine nucleobase catabolic process
GO:0006210 thymine catabolic process
GO:0006212 uracil catabolic process
GO:0006213 pyrimidine nucleoside metabolic process
GO:0009112 nucleobase metabolic process
GO:0009116 nucleoside metabolic process
GO:0009164 nucleoside catabolic process
GO:0019439 aromatic compound catabolic process
GO:0019482 beta-alanine metabolic process
GO:0019859 thymine metabolic process
GO:0019860 uracil metabolic process
GO:0034655 nucleobase-containing compound catabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0046113 nucleobase catabolic process
GO:0046135 pyrimidine nucleoside catabolic process
GO:0046700 heterocycle catabolic process
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0051262 protein tetramerization
GO:0051289 protein homotetramerization
GO:0072527 pyrimidine-containing compound metabolic process
GO:0072529 pyrimidine-containing compound catabolic process
GO:1901136 carbohydrate derivative catabolic process
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1901657 glycosyl compound metabolic process
GO:1901658 glycosyl compound catabolic process
Molecular Function GO:0002054 nucleobase binding
GO:0002058 uracil binding
GO:0002059 thymine binding
GO:0002061 pyrimidine nucleobase binding
GO:0004157 dihydropyrimidinase activity
GO:0016597 amino acid binding
GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds
GO:0016812 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amides
GO:0031406 carboxylic acid binding
GO:0043168 anion binding
GO:0051219 phosphoprotein binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00240 Pyrimidine metabolism
hsa00410 beta-Alanine metabolism
hsa00770 Pantothenate and CoA biosynthesis
hsa00983 Drug metabolism - other enzymes
hsa01100 Metabolic pathways
Reactome R-HSA-1430728: Metabolism
R-HSA-15869: Metabolism of nucleotides
R-HSA-73621: Pyrimidine catabolism
R-HSA-73848: Pyrimidine metabolism
Summary
SymbolDPYS
Namedihydropyrimidinase
Aliases DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DPYS and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolDPYS
Namedihydropyrimidinase
Aliases DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DPYS in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDPYS
Namedihydropyrimidinase
Aliases DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DPYS in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2550.675
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.3990.146
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.470.0692
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.190.753
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3870.727
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.9160.467
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.1410.181
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0460.972
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11122.2750.0781
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2730.88
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.8170.764
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6880.0362
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DPYS in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.46.80.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.48.5-1.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDPYS
Namedihydropyrimidinase
Aliases DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DPYS. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDPYS
Namedihydropyrimidinase
Aliases DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DPYS. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DPYS.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDPYS
Namedihydropyrimidinase
Aliases DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DPYS. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDPYS
Namedihydropyrimidinase
Aliases DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DPYS expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDPYS
Namedihydropyrimidinase
Aliases DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DPYS and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDPYS
Namedihydropyrimidinase
Aliases DHPase; dihydropyrimidine amidohydrolase; hydantoinase
Chromosomal Location8q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DPYS collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.